Help

Ubiquitin D Polyclonal Antibody, APC Conjugated

Applications

  • WB

Reactivity

  • Human
  • Mouse

Predicted Reactivity

  • Rat
  • Dog
  • Cow
  • Sheep
  • Pig
  • Horse
  • Rabbit
Overview
Catalog # bs-13006R-APC-100uL
Product Name Ubiquitin D Polyclonal Antibody, APC Conjugated
Applications
WB
Reactivity Human, Mouse
Predicted Reactivity Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit
Specifications
Conjugation APC
Host Rabbit
Source KLH conjugated synthetic peptide derived from human Ubiquitin D
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 10537
Swiss Prot O15205
Subcellular location Cytoplasm, Nucleus
Synonyms FAT10; UBD-3; GABBR1; Ubiquitin D; Diubiquitin; Ubiquitin-like protein FAT10; UBD
Background Ubiquitin-like protein modifier which can be covalently attached to target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1L-dependent manner. Probably functions as a survival factor. Conjugation ability activated by UBA6. Promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). Regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. Required for TNF-alpha-induced p65 nuclear translocation in renal tubular epithelial cells (RTECs). May be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T-cell responses. Mediates mitotic non-disjunction and chromosome instability, in long-term in vitro culture and cancers, by abbreviating mitotic phase and impairing the kinetochore localization of MAD2L1 during the prometaphase stage of the cell cycle. May be involved in the formation of aggresomes when proteasome is saturated or impaired. Mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN).
Application Dilution
WB 1:300-5000

Frequently asked questions

Which applications is Ubiquitin D Polyclonal Antibody, APC Conjugated (bs-13006R-APC) validated for, and at what dilution?

bs-13006R-APC is validated for WB (1:300-5000). These are recommended starting dilutions; optimal dilutions should be determined by the end user.

Which species does Ubiquitin D Polyclonal Antibody, APC Conjugated (bs-13006R-APC) react with?

Tested reactivity: Human, Mouse. Predicted reactivity (expected from sequence homology but not yet tested): Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit.

How should bs-13006R-APC be stored?

Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

What immunogen was used to raise Ubiquitin D Polyclonal Antibody, APC Conjugated (bs-13006R-APC)?

KLH conjugated synthetic peptide derived from human Ubiquitin D

What are the excitation and emission wavelengths of the APC conjugate (bs-13006R-APC)?

APC on bs-13006R-APC: excitation / emission 650nm/660nm.